AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05895357 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Musictherapy
Description: The patients were asked about the type of music they wanted to listen to. Especially in the last meta-analyses, it was determined that listening to the music that patients chose was more effective (Witten 2020). For this reason, after the intervention group is asked about the music they want to listen to, the music they want will be played from the music application.
Study NCT00681148 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Botox injection
Description: Intraprostatic injection of Botox (100 units for \< 30 cc prostate; 200 units for > 30 cc prostate) administering 2 transperineal injections into both lateral lobes of the prostate (25-50 units per injection), just 5-10 mm proximal to the bladder neck.
Study NCT00681148 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline injection
Description: Saline injection, administering 2 transperineal injections into both lateral lobes of the prostate (1-2 cc per injection), just 5-10 mm proximal to the bladder neck.
Study NCT04487678 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Ketone ester supplement
Description: Participants taking part in this study will receive a drink containing either 141 or 282 mg/kg bodyweight of ketone esters in a randomised order. These doses are in line with recommendations by the company HVMN from which the supplements for this study will be obtained.
Study NCT04985786 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy for reducing risk behaviors
Description: Cognitive Behavioral Therapy to reduce risk behaviors and increase risk perception that combines a standardised face-to-face group therapy before discharge from in-patient treatment and a standardised ecological momentary intervention delivered by mobile phones during the four weeks after discharge. For SZ the target risk behavior is medication non-adherence and for AUD and AUD \& SZ it is alcohol use.
Study NCT04985786 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive Behavioral Therapy for increasing non-risk behaviors
Description: Cognitive Behavioral Therapy to increase non-risk behaviors that combines a standardised face-to-face group therapy before discharge from in-patient treatment and a standardised ecological momentary intervention delivered by mobile phones during the four weeks after discharge. In this control intervention for patient groups the target behavior is cognitive exercises.
Study NCT04862442 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Qigong exercises
Description: Specific Qigong exercises 1- Painting the rainbow 2-Raising the arms 3-Looking at the moon 4- Pushing the waves
Study NCT05766527 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: KM602
Description: Multiple dose levels of KM602 will be administered, including 0.01 mg/kg QW, 0.1 mg/kg QW, 0.6 mg/kg QW, 3 mg/kg QW, and 10 mg/kg QW. KM602 is administered intravenously once a week, and each cycle is 21 days.
Study NCT06329323 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Blood test
Description: Serum and plasma microRNA quantification
Study NCT06329323 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Pathology specimen miRNA expression
Description: Pathology specimen mirNA expression - ALL MOGCT; OPTIONAL for BOGCT
Study NCT06179147 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: cervical traction
Description: Traction of the uterine cervix applied in the study; It is the process of pulling the anterior and posterior lips of the cervix towards the intraoitus, downwards and backwards for approximately 90 seconds using overpens. Traction is applied until the cervix reaches the level of vaginal introitus. It is a cost-effective, new, simple intervention with no reported adverse effects.
Study NCT06508203 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: arthrocentesis with lactate ringer only
Description: classical arthrocentesis with lactate ringer only (control group).
Study NCT06508203 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: arthrocentesis with lactate ringer followed by injection with piroxicam 2 ml (40mg)
Description: classical arthrocentesis with lactate ringer followed by injection with piroxicam 2 ml (40mg)
Study NCT06610643 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: combination therapy
Description: A combination of 5-day remdesivir and 10-day Nirmatrelvir/Ritonavir
Study NCT06610643 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SOC
Description: Standard of care
Study NCT06610643 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SOC
Description: Standard of care
Study NCT06611865 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Intraligamentary anaesthesia
Description: Injection of anesthetic solution into the intraligamentary space along the long axis of a tooth root using a pressure syringe.
Study NCT05951270 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Apple Polyphenols
Description: ApplePhenon® is prepared from unripe green apples (malus domestica) and contains a large amounts of polyphenols. The supplement contains 63.8% procyanidins, 12.4% flavon-3-ols, 6.5% chalcones and 10.8% phenolcarboxylic acids
Study NCT05951270 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: The placebo used in this study is 1100 mg maltodextrin (Avebe, Veendam, the Netherlands). This product is an enzymatically converted potato starch. The flavor and color will have a similar/identical appearance and taste as all mentioned antioxidants.
Study NCT05688631 — intervention group
Intervention type: OTHER
Intervention: Dietary antioxidant intake
Description: Decreased intake of dietary antioxidant is associated with decreased thiol disulfide homeostasis parameters in diabetic and healthy participants.
Study NCT06349447 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: LED
Description: 308 nm LED light was utilized to induce an vivo PIE/PIH model on the thigh of subjects. The irradiation dose was 1.5 MED. Five circular experimental lesions measuring 1.5 × 1.5 cm were selected on the thighs, categorizing into five groups: control group, 830 nm LED treatment group, 590 nm LED treatment group, 830 nm LED prevention group and 590 nm LED prevention group. 830 nm LED and 590 nm LED were irradiated, respectively. For therapeutic irradiation, the PIH model was induced on D1, and 830 nm (60 J/cm2, 50 mW/cm2) and 590 nm LED (20 J/cm2, 20 mW/cm2) were irradiated on D0, D1, D3, D6 and D8, respectively. For preventive irradiation, 830 nm and 590 nm LED were irradiated on D0, D1, D3, D6 and D8, respectively, and the PIE/PIH model was induced on D9.
Study NCT06349447 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: without any LED exposition
Description: without any LED exposition
Study NCT06611865 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Inferior alveolar nerve block
Description: Anaesthetic injection into the pterygomandibular space to block the Inferior alveolar nerve at the mandibular foramen point.
Study NCT06612476 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Interleukin 6-guided antibiotic therapy
Description: In Interleukin-6 group, antibiotic prescription decisions will made according to the results of IL-6.
Study NCT06612476 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GOLD-guided antibiotic therapy
Description: In guideline group, antibiotic prescription decisions will made according to the recommendations of GOLD guideline.
Study NCT06612814 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluzoparib
Description: Parp inhibitor
Study NCT06612814 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dalpiciclib
Description: CDK4/6 inhibitor
Study NCT06612814 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dalpiciclib
Description: CDK4/6 inhibitor
Study NCT06612814 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fulvestrant/AI
Description: Endocrine therapy
Study NCT06612814 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fulvestrant/AI
Description: Endocrine therapy
Study NCT06612996 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tramadol
Description: Intravenous tramadol
Study NCT06612996 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Magnesium sulphate
Description: Intravenous magnesium sulphate
Study NCT06612996 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: Normal saline
Study NCT06612658 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: A novel, proprietary encapsulated form of Capsicum extract in beadlet form standardized to 2% capsaicinoids
Description: This study will investigate the effect of the supplement on exercise performance.
Study NCT06612658 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: A novel, proprietary encapsulated form of Capsicum extract in beadlet form standardized to 2% capsaicinoids
Description: This study will investigate the effect of the supplement on exercise performance.
Study NCT06453733 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Crainio
Description: Crainio device comprises a forehead-mounted sensor containing infrared light sources that can illuminate the deep brain tissue of the frontal lobe. Photodetectors in the sensor detect the backscattered light, which is modulated by pulsation of the cerebral arteries. A control unit processes the backscattered light (called the photoplethysmogram, PPG) and transmits it to a computer device to train ML models that will estimate ICP offline.
Study NCT05231889 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Silverway guidewire
Description: The Silverway guidewire is a newly developed guidewire to overcome the problems the Radifocus guidewire has
Study NCT05231889 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Radifocus guidewire
Description: The Radifocus guidewire is a hydrophilic coated guidewire that is used when a standard J-tip guidewire does not cross a vascular anomaly
Study NCT06432478 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 3D-printed custom applicator
Description: 3D-printed custom applicator
Study NCT05828953 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anlotinib
Description: Drug: Anlotinib The dose of nintedanib hydrochloride is 8mg per dose, taken orally once daily before breakfast. The drug is taken continuously for 2 weeks, followed by a 1-week break, until week 52, disease progression, or the occurrence of intolerable adverse events. If a dose is missed and the next dose is due within 12 hours, it should not be made up.~Drug: Placebo Placebo, taken orally once daily before breakfast. Taken continuously for 2 weeks, followed by a 1-week break, until week 52, disease progression, or the occurrence of intolerable adverse events. If a dose is missed and the next dose is due within 12 hours, it should not be made up.
Study NCT05828953 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo, taken orally once daily before breakfast. Taken continuously for 2 weeks, followed by a 1-week break, until week 52, disease progression, or the occurrence of intolerable adverse events. If a dose is missed and the next dose is due within 12 hours, it should not be made up.
Study NCT06487715 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: albumin-bound paclitaxel (260 mg/m2, d1)
Description: 260 mg/m2, d1)
Study NCT06487715 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S-1
Description: 80 mg/m2, d1-14
Study NCT06487715 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sintilimab
Description: 200 mg, d1
Study NCT06487715 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bevacizumab
Description: First two cycles : intraperitoneally 7.5 mg/m2 Maintenance period: intravenously 7.5 mg/m2
Study NCT05707390 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mezigdomide
Description: Specified dose on specified days
Study NCT05306717 — intervention group
Intervention type: OTHER
Intervention: Questionnaire
Description: The study will compare the rates of isolation and restraint of the two sectoral admission units welcoming people in care without consent for a period of one year. The impact of the QPGE on the satisfaction scores will be systematically evaluated by a self-questionnaire for patients at the end of hospitalization. The QPGE is administered by a nurse during the reception interview of the patient in the unit.
Study NCT05819372 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Zygomaticomaxillary fracture repair
Description: A cone beam CT (CBCT) scan of the patient will be used to create a 3D scanned image of zygomaticomaxillary complex fracture (ZMC)~* 3D images will be introduced to finite element (FA) software to evaluate Stresses (MPa), Micromotion (microns), and Life time (cycle) For each model and determine which point of fixation is the best~* After application this point of fixation on the patient~* Finite element analysis will be done again to verify the previous results
Study NCT05676788 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hyperspectral Imaging
Description: Identification of the intersegmental plane
Study NCT06312384 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: 3D Surgical Template on the Contour of Bone Augmentation, in Patient With Labial Alveolar Ridge Defect and Simultaneous Implantation
Description: a two-piece tooth-supported surgical template will fabricated through 3D printing technology before surgery base on the digital simulation of bone graft contour.Sticky bone will placed into the defect under the guidance of the template to form customized sticky bone and will be covered with collagen membrane.
Study NCT06312384 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: conventional guided bone regeneration,in Patient With Labial Alveolar Ridge Defect and Simultaneous Implantation
Description: The defected site will be grafted with sticky bone (particulate bone substitute mixed with injectable platelet-rich fibrin (i-PRF)) and will be covered with collagen membrane.
Study NCT05660252 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Collaborative request
Description: The relative is approached by the clinical team and an organ procurement coordinator together.
Study NCT05122624 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PredicTB score
Description: This is an easy-to-use clinical risk score designed to improve early management of tuberculosis in highly resource-constrained settings where same-day microbiological testing is unavailable. It consists of readily accessible demographic and clinical data and is scored from 1-10.~We will train clinic staff in eight clinics (four study clinics and four comparison clinics) on the Ugandan standard of care for the diagnosis and treatment of TB. In addition, in the four study clinics, we will provide training on the PredicTB score.
Study NCT05381454 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mitoquinone/mitoquinol mesylate
Description: Mitoquinone/mitoquinol mesylate
Study NCT05909553 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Oral; Tablet
Study NCT04878068 — intervention group
Intervention type: DEVICE
Intervention: Theram COVID-19 Rapid Antigen Test
Description: The Therma COVID-19 Rapid Antigen Test is an in vitro rapid, lateral flow immunoassay intended for the qualitative detection of SARS-CoV-2 nucleocapsid protein antigens in human saliva specimens. This test is intended for near-patient use at the point-of-care or lay person, self-use in a non-laboratory or home setting using saliva samples from individuals with or without symptoms of COVID-19.
Study NCT06067867 — intervention group
Intervention type: OTHER
Intervention: Data extraction from medical files
Description: Data extraction from medical files
Study NCT05564000 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dating Violence Prevention Program
Description: We designed and constructed the e-learning platform as an education program on dating violence based on the theory of planned behavior to evaluate the effectiveness of the programs in improving dating violence myths, bystander help-giving attitude, subjective norms, self-efficacy, intention, and behavior.
Study NCT05057871 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pulse electromagnetic field therapy
Description: It was applied with an electromagnetic field device (ASA Pmt Quatro Pro, ASA Srl Via A.Volta 9-36057 Italia) at 50 Hz frequency, 85 Gauss (8.5 milliTesla) intensity and for 30 minutes. The treatment period was 5 days a week for 4 weeks, in total. It was applied as 20 sessions.~Therapeutic Exercise As a therapeutic exercise program; active shoulder ROM, isometric and progressive strengthening exercises for shoulder girdle muscles, codman pendulum exercises will be performed. It was planned to implement a total of 20 sessions 5 days a week for 4 weeks, for approximately 30 minutes. Exercises will be performed by a trained (at least 5 years experienced) physiotherapist, three times a day, in 3 sets, 10 repetitions.
Study NCT05057871 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham pulse electromagnetic field therapy
Description: Sham pulse electromagnetic field therapy was applied five sessions a week for four weeks, for a total of 20 sessions a day, using electromagnetic field device (ASA Pmt Quatro Pro, ASA Srl Via A.Volta 9-36057 Italy) without current flowing through the device.~Therapeutic Exercise As a therapeutic exercise program; active shoulder ROM, isometric and progressive strengthening exercises for shoulder girdle muscles, codman pendulum exercises will be performed. It was planned to implement a total of 20 sessions 5 days a week for 4 weeks, for approximately 30 minutes. Exercises will be performed by a trained (at least 5 years experienced) physiotherapist, three times a day, in 3 sets, 10 repetitions.
Study NCT05677425 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Temperature measurement
Description: Temperature measurement in the renal pelvis during ureteroscopic laser activation.
Study NCT06407219 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Robot Assisted Gait Training
Description: The Trexo robotic gait trainer will be used to facilitate physical activity in people who cannot walk independently, either at all or without the use of assistive gait aids (ie. walkers or canes). Session length will be determined by the participant's perceived fatigue level (ie. the session will run until the participant feels they want to or need to stop), and will not exceed 1 hour of training time.
Study NCT05177640 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 99mTc-Duramycin
Description: This is a single dose study of 99mTc-duramycin in healthy volunteers who will undergo serial SPECT scanning
Study NCT04819789 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fermotein™ dry powder porridge
Description: At one out of four test days: Fermotein™ dry powder mixed with water and a few drops of food grade flavor concentrates, to obtain a porridge representing a 20g protein load.
Study NCT04819789 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fermotein™ wet porridge
Description: At one out of four test days: Fermotein™ wet mixed with water and a few drops of food grade flavor concentrates, to obtain a porridge representing a 20g protein load.
Study NCT04819789 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fermotein™ modified wet porridge
Description: At one out of four test days: Fermotein™ modified wet mixed with water and a few drops of food grade flavor concentrates, to obtain a porridge representing a 20g protein load.
Study NCT04819789 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Mycoprotein porridge (matching control)
Description: At one out of four test days: Mycoprotein (Quorn) mixed with water and a few drops of food grade flavor concentrates, to obtain a porridge representing a 20g protein load.
Study NCT04899115 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Starting the last day of oral vancomycin (Day 1), subjects randomized to this arm will take 5 capsules of placebo for 14 days taken once daily.
Study NCT04899115 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VE303
Description: Starting the last day of oral vancomycin (Day 1), subjects randomized to this arm will take 5 capsules of VE303 taken daily for 14 days.~The quantity of each strain is proportioned to assure a specific per-strain per-capsule titer. The 8 strains are blended together with a micro-crystalline cellulose flow agent and placed in enteric capsules.
Study NCT04899115 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: oral vancomycin
Description: All enrolled subjects will receive 5 days of oral vancomycin 125 mg four times a day (q.i.d).
Study NCT04899115 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oral vancomycin
Description: All enrolled subjects will receive 5 days of oral vancomycin 125 mg four times a day (q.i.d).
Study NCT06491355 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mfolfox6 and hlx04 regimen and Serplulimab
Description: mfolfox6 and hlx04 regimen induction therapy followed by combined treatment with slulimumab in the experimental arm. In the active comparator. only with mfolfox6 and hlx04 regimen treatment.
Study NCT06491355 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: mfolfox6 and hlx04 regimen
Description: In the active comparator. only with mfolfox6 and hlx04 regimen treatment.
Study NCT05563545 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CAR-NK-CD19 Cells
Description: CAR-NK-CD19 Cells, 1-3×10\^7 /KG, treatment follows a lymphodepletion. Drug: Fludarabine Recommendation: 25-30 mg/m2 (D-5\~D-3), determined by tumor burden at baseline. Drug: Cyclophosphamide Recommendation: 250-300 mg/m2 (D-5\~D-3), determined by tumor burden at baseline.